Baxter International Inc (BAX) was Reiterated by RBC Capital Mkts to “Sector Perform” according to the research note released today. The brokerage firm has raised the Price Target to $ 47 from a previous price target of $40 . RBC Capital Mkts advised their investors in a research report released on Apr 27, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 40 from a previous price target of $37 .
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Baxter International Inc opened for trading at $43.1 and hit $43.59 on the upside on Friday, eventually ending the session at $43.32, with a gain of 0.72% or 0.31 points. The heightened volatility saw the trading volume jump to 3,33,86,654 shares. Company has a market cap of $23,734 M.
In a different news, on Apr 6, 2016, John D Forsyth (director) sold 1,887 shares at $41.75 per share price. According to the SEC, on Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price. On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price, according to the Form-4 filing with the securities and exchange commission.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.